Wave Life Sciences (WVE) has attracted investor attention after recent share price swings, with the stock closing at US$5.79. The move comes against a backdrop of mixed short term and longer term returns.

Recent trading puts Wave Life Sciences on a weak near term trend, with the 7 day share price return down 5.55% and the 90 day share price return down 21.54%. However, the 3 year total shareholder return of 48.08% shows a much stronger longer term picture.

If recent volatility has you thinking about diversification, this could be a good moment to look across the market and check out 39 healthcare AI stocks.

Is Wave Life Sciences’ recent pullback a sign that the RNA pipeline and partnerships are being reassessed, or is it mainly sentiment resetting after a strong three year run? And what does that mean for valuation next?

Most Popular Narrative: 73.9% Undervalued

Against the last close of $5.79, the most followed narrative for Wave Life Sciences is built around a fair value of $22.19, leaving a wide valuation gap that hinges on how the RNA pipeline plays out.

The upcoming clinical data readouts for key programs (AATD with WVE-006 and obesity with WVE-007) in late 2025 and early 2026 represent potential inflection points, supported by strong early efficacy and favorable safety, and, if positive, could significantly expand revenue opportunities in large, underserved markets driven by an aging population and rising chronic disease prevalence.

Curious what has to happen in those trials to support a fair value almost four times the current share price, and which revenue, margin and valuation assumptions sit underneath that number.

Result: Fair Value of $22.19 (UNDERVALUED)

However, Wave Life Sciences still faces meaningful risks, including widening losses, with net income at a loss of US$183.6 million, and heavy reliance on a small set of pipeline programs.

Another View: What Wave Life Sciences’ Sales Multiple Is Telling You

The narrative around Wave Life Sciences leans heavily on future upside, but current pricing tells a different story. The stock trades on a P/S of 15.5x, compared with 6.7x for the US Pharmaceuticals industry and 1.2x for peers, while the fair ratio is 1.3x. That gap implies investors are already paying a steep premium for unproven earnings. The key question is how much execution risk you are comfortable with.

Next Steps

With sentiment on Wave Life Sciences clearly split between optimism on rewards and concern about risks, this is a moment to move quickly and examine the underlying data yourself. To weigh that balance directly and see how others are thinking about it, take a closer look at the 1 key reward and 2 important warning signs.

Looking for more investment ideas beyond Wave Life Sciences?

Do not stop with Wave Life Sciences; expand your watchlist now by scanning other opportunities that could fit your goals before they move out of reach.

• Target potential mispricing by checking companies that screen as high quality and undervalued through the 50 high quality undervalued stocks.
• Prioritise stability and capital preservation by reviewing stocks in the 81 resilient stocks with low risk scores that score well on resilience.
• Unearth underfollowed opportunities by browsing the screener containing 20 high quality undiscovered gems that pair solid fundamentals with limited current attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.